Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**优威克** is Zhifei's marketed 23-valent pneumococcal polysaccharide vaccine for prevention of infections caused by vaccine-included *Streptococcus pneumoniae* serotypes in people aged 2 years and older. Developed and manufactured by Beijing Zhifei Lvzhu Biopharmaceutical, it contains purified capsular polysaccharide antigens from 23 pneumococcal serotypes and induces serotype-specific humoral antibody responses. It is a non-conjugated polysaccharide vaccine and is not expected to protect against pneumococcal serotypes not represented in the formulation. Zhifei lists 优威克 as its proprietary 23-valent pneumococcal polysaccharide vaccine product, and the product received Chinese marketing authorization in 2023. ([zhifeishengwu.com](https://www.zhifeishengwu.com/zh_CN/pro/27.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 优威克.